SL Science Holding Limited reported a 23% increase in net revenue to $1.39 million for the first half of 2026, driven by a shift to B2B wholesale distribution and improved supplier terms. The company expanded its gross margin to 40.2% and increased R&D spending by 72%, focusing on oncology therapies including CD-19 Armed-T and Gamma Delta T cell therapies targeting brain and pancreatic cancers. Key milestones include securing exclusive global rights for Gamma Delta T cell applications and progressing regulatory submissions with the FDA. Despite a net loss of $2.16 million, SL Science strengthened its cash position to $8.31 million following a $7.8 million PIPE financing and Nasdaq listing in June 2026. The company aims to become a global leader in cellular therapies addressing unmet medical needs.
SL Science Holding Limited's first half 2026 financial results provide context for readers following health-related stocks. As of Oct 27, 2026 03:11 WIB, among 150 priced Health-sector US stocks on Pluang, 80 rose and 70 fell. Notable movers include Summit Therapeutics Inc (SMMT) at USD 14.48 with a 6.37% decline and balanced Pluang order activity, Smith & Nephew plc (SNN) at USD 30.85 gaining 5.54% but with 100% sell orders, and Tango Therapeutics Inc. (TNGX) at USD 22.09 down 5.36% yet showing 86% buy orders and a very short typical hold time of 2 days.
Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...
Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...
S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...
Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...
Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...
